---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-036246"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:33:11.587656+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics FY2022 net loss $54.6M; cash $65.5M plus $50M from Flame acquisition

## Summary
- Net loss $54.6M for 2022 (vs $40.6M in 2021); R&D expenses $45M (vs $32.2M).
- Cash $65.5M at Dec 31, 2022; excludes ~$50M cash from Flame acquisition in Jan 2023.
- Flame acquisition: issued ~19.8M common shares + 136.8k preferred convertible into 136.8M common shares (subject to approval).
- DKN-01: Part C DisTinGuish randomized trial enrollment expected completion late 2023; Part A DeFianCe CRC study enrollment near completion.
- BeiGene's option for DKN-01 in Asia expired; clinical collaboration continues for DisTinGuish Part C.

## SEC filing metadata
- accession: 0001104659-23-036246
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/0001104659-23-036246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/tm2310372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-036246
- JSON: https://secwatch.observer/filing/0001104659-23-036246.json
- Plain text: https://secwatch.observer/filing/0001104659-23-036246.txt

## Key facts
- Earnings Releases
  CYPHERPUNK TECHNOLOGIES INC. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 24, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/0001104659-23-036246-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.